Neuphoria Therapeutics Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Neuphoria Therapeutics Inc. (NEUP) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $351.60 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-09-18
- Neuphoria Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $76.34K.
- Neuphoria Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $70.29K, a 243.43% increase year-over-year.
- Neuphoria Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-12-31 was $93.70K, a 346.83% increase year-over-year.
- Neuphoria Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $111.28K, a 316.21% increase year-over-year.
- Neuphoria Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2026 was $351.60K, a 90.68% increase from fiscal 2025.
- Neuphoria Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $184.40K, a 77.37% decline from fiscal 2024.
- Neuphoria Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $814.81K, a 39.43% decline from fiscal 2023.
- Neuphoria Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $1.35M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $76.34K derived: 10-K 12 month − 3 quarters · filed 2026-09-18 | $146.62K derived: sum of 2 quarters · filed 2026-09-18 | $240.32K derived: sum of 3 quarters · filed 2026-09-18 | $351.60K 10-K · filed 2026-09-18 |
| 2026-03-31 | $70.29K 10-Q · filed 2026-05-15 | $163.99K derived: sum of 2 quarters · filed 2026-05-15 | $275.26K derived: sum of 3 quarters · filed 2026-05-15 | |
| 2025-12-31 | $93.70K 10-Q · filed 2026-05-15 | $204.98K derived: sum of 2 quarters · filed 2026-05-15 | ||
| 2025-09-30 | $111.28K 10-Q · filed 2026-05-15 | |||
| 2025-06-30 | $184.40K 10-K · filed 2026-09-18 | |||
| 2025-03-31 | $20.47K 10-Q · filed 2026-05-15 | $41.44K derived: sum of 2 quarters · filed 2026-05-15 | $68.17K derived: sum of 3 quarters · filed 2026-05-15 | |
| 2024-12-31 | $20.97K 10-Q · filed 2026-05-15 | $47.71K derived: sum of 2 quarters · filed 2026-05-15 | ||
| 2024-09-30 | $26.74K 10-Q · filed 2026-05-15 | |||
| 2024-06-30 | $814.81K 10-K · filed 2025-09-29 | |||
| 2024-03-31 | $40.03K 10-Q · filed 2025-05-20 | $786.97K derived: sum of 2 quarters · filed 2025-05-20 | $927.41K derived: sum of 3 quarters · filed 2025-05-20 | |
| 2023-12-31 | $746.94K 10-Q · filed 2025-05-20 | $887.38K derived: sum of 2 quarters · filed 2025-05-20 | ||
| 2023-09-30 | $140.45K 10-Q · filed 2025-05-20 | |||
| 2023-06-30 | $1.35M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |